Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Sabizabulin · VERU-111

Small molecule · Inhibitor of alpha-tubulin (TUBA1A) and beta-tubulin (TUBB) · developed by Veru

Phase 3 Most advanced trial (none active)

VERU Developer

3 Registered trials

What is Sabizabulin?

Sabizabulin is an orally bioavailable small molecule tubulin inhibitor that binds the colchicine-binding site of alpha- and beta-tubulin, blocking microtubule polymerization. It disrupts tumor vasculature and induces apoptosis in tumor cells, and may inhibit viral replication and pro-inflammatory cytokine release. It is studied in metastatic breast cancer and SARS-CoV infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: VERU-111
Drug type: Small molecule
Targets: alpha-tubulin (TUBA1A), beta-tubulin (TUBB), androgen receptor (AR) (secondary target)
Mechanism: Inhibitor of alpha-tubulin (TUBA1A) and beta-tubulin (TUBB)
Pathways: microtubule polymerization, cell cycle arrest, apoptosis, angiogenesis
Therapy area: Infectious disease, Oncology
Developer: Veru Inc. (VERU)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 37L1JX37J5

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04842747	Phase 3	SARS-CoV Infection	Completed	VERU
NCT05079360	Phase 2	Metastatic Breast Cancer	Withdrawn	VERU
NCT05008510	Phase 2	Metastatic Triple Negative Breast Cancer	Withdrawn	VERU

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Breast CancerMetastatic Triple Negative Breast CancerSARS-CoV Infection

Other drugs acting on TUBA1A / TUBB

Nab-paclitaxel FDA approved

More from Veru

VERU-100 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the VERU page.

Follow VERU, the company behind Sabizabulin

See VERU's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VERU catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z